CAP (ANGPTL4 ASO)
Community-Acquired Pneumonia (CAP) / ARDS Prevention
PreclinicalActive (Research via partnership)
Key Facts
Indication
Community-Acquired Pneumonia (CAP) / ARDS Prevention
Phase
Preclinical
Status
Active (Research via partnership)
Company
About Lipigon Pharmaceuticals
Lipigon Pharmaceuticals is a clinical-stage biotech focused on developing first-in-class drugs for lipid metabolism disorders and related cardiometabolic diseases. Its strategy leverages deep target validation expertise and external platform partnerships to advance a pipeline of RNA-based and small molecule therapeutics. Key achievements include a Phase II-ready lead asset (Lipisense), strategic partnerships in China (Leaderna) and for discovery (HitGen), and a foundation in renowned Umeå University research.
View full company profile